155 related articles for article (PubMed ID: 32858418)
1. Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.
Glas C; Dietschreit JCB; Wössner N; Urban L; Ghazy E; Sippl W; Jung M; Ochsenfeld C; Bracher F
Eur J Med Chem; 2020 Nov; 206():112676. PubMed ID: 32858418
[TBL] [Abstract][Full Text] [Related]
2. Development of hetero-triaryls as a new chemotype for subtype-selective and potent Sirt5 inhibition.
Glas C; Naydenova E; Lechner S; Wössner N; Yang L; Dietschreit JCB; Sun H; Jung M; Kuster B; Ochsenfeld C; Bracher F
Eur J Med Chem; 2022 Oct; 240():114594. PubMed ID: 35853430
[TBL] [Abstract][Full Text] [Related]
3. Identification of 2-hydroxybenzoic acid derivatives as selective SIRT5 inhibitors.
Liu Y; Debnath B; Kumar S; Lombard DB; Neamati N
Eur J Med Chem; 2022 Nov; 241():114623. PubMed ID: 35932566
[TBL] [Abstract][Full Text] [Related]
4. Structure-based discovery of new selective small-molecule sirtuin 5 inhibitors.
Liu S; Ji S; Yu ZJ; Wang HL; Cheng X; Li WJ; Jing L; Yu Y; Chen Q; Yang LL; Li GB; Wu Y
Chem Biol Drug Des; 2018 Jan; 91(1):257-268. PubMed ID: 28756638
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-Based Inhibitors of the Human Sirtuin 5 Deacylase: Structure-Activity Relationship, Biostructural, and Kinetic Insight.
Rajabi N; Auth M; Troelsen KR; Pannek M; Bhatt DP; Fontenas M; Hirschey MD; Steegborn C; Madsen AS; Olsen CA
Angew Chem Int Ed Engl; 2017 Nov; 56(47):14836-14841. PubMed ID: 29044784
[TBL] [Abstract][Full Text] [Related]
6. Cyclic Tripeptide-based Potent and Selective Human SIRT5 Inhibitors.
Jiang Y; Zheng W
Med Chem; 2020; 16(3):358-367. PubMed ID: 31161996
[TBL] [Abstract][Full Text] [Related]
7. Docking and binding free energy calculations of sirtuin inhibitors.
Karaman B; Sippl W
Eur J Med Chem; 2015 Mar; 93():584-98. PubMed ID: 25748123
[TBL] [Abstract][Full Text] [Related]
8. Role of the Substrate Specificity-Defining Residues of Human SIRT5 in Modulating the Structural Stability and Inhibitory Features of the Enzyme.
Yu J; Haldar M; Mallik S; Srivastava DK
PLoS One; 2016; 11(3):e0152467. PubMed ID: 27023330
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin.
Schuetz A; Min J; Antoshenko T; Wang CL; Allali-Hassani A; Dong A; Loppnau P; Vedadi M; Bochkarev A; Sternglanz R; Plotnikov AN
Structure; 2007 Mar; 15(3):377-89. PubMed ID: 17355872
[TBL] [Abstract][Full Text] [Related]
10. Sirt5 deacylation activities show differential sensitivities to nicotinamide inhibition.
Fischer F; Gertz M; Suenkel B; Lakshminarasimhan M; Schutkowski M; Steegborn C
PLoS One; 2012; 7(9):e45098. PubMed ID: 23028781
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins).
Trapp J; Meier R; Hongwiset D; Kassack MU; Sippl W; Jung M
ChemMedChem; 2007 Oct; 2(10):1419-31. PubMed ID: 17628866
[TBL] [Abstract][Full Text] [Related]
12. Chemical probing of the human sirtuin 5 active site reveals its substrate acyl specificity and peptide-based inhibitors.
Roessler C; Nowak T; Pannek M; Gertz M; Nguyen GT; Scharfe M; Born I; Sippl W; Steegborn C; Schutkowski M
Angew Chem Int Ed Engl; 2014 Sep; 53(40):10728-32. PubMed ID: 25111069
[TBL] [Abstract][Full Text] [Related]
13. Pyrazolone derivatives as potent and selective small-molecule SIRT5 inhibitors.
Yao J; Yin Y; Han H; Chen S; Zheng Y; Liang B; Wu M; Shu K; Debnath B; Lombard DB; Wang Q; Cheng K; Neamati N; Liu Y
Eur J Med Chem; 2023 Feb; 247():115024. PubMed ID: 36543033
[TBL] [Abstract][Full Text] [Related]
14. Sensitive fluorogenic substrates for sirtuin deacylase inhibitor discovery.
Yang LL; Wang HL; Yan YH; Liu S; Yu ZJ; Huang MY; Luo Y; Zheng X; Yu Y; Li GB
Eur J Med Chem; 2020 Apr; 192():112201. PubMed ID: 32163813
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of 2,4,6- trisubstituted triazine derivatives as new nonpeptide small-molecule SIRT5 inhibitors.
Wang L; Hu L; Deng J; Hou S; Mou L; Lei P; Chen X; Liu J; Jiang Y; Xiong R; Tian X; Zhang W; Li R; Yang W; Yang L
Bioorg Med Chem; 2023 Oct; 93():117455. PubMed ID: 37643500
[TBL] [Abstract][Full Text] [Related]
16. Discovery of new human Sirtuin 5 inhibitors by mimicking glutaryl-lysine substrates.
Yang F; Su H; Deng J; Mou L; Wang H; Li R; Dai QQ; Yan YH; Qian S; Wang Z; Li GB; Yang L
Eur J Med Chem; 2021 Dec; 225():113803. PubMed ID: 34461505
[TBL] [Abstract][Full Text] [Related]
17. The bicyclic intermediate structure provides insights into the desuccinylation mechanism of human sirtuin 5 (SIRT5).
Zhou Y; Zhang H; He B; Du J; Lin H; Cerione RA; Hao Q
J Biol Chem; 2012 Aug; 287(34):28307-14. PubMed ID: 22767592
[TBL] [Abstract][Full Text] [Related]
18. Benzimidazoles as new scaffold of sirtuin inhibitors: green synthesis, in vitro studies, molecular docking analysis and evaluation of their anti-cancer properties.
Yoon YK; Ali MA; Wei AC; Shirazi AN; Parang K; Choon TS
Eur J Med Chem; 2014 Aug; 83():448-54. PubMed ID: 24992072
[TBL] [Abstract][Full Text] [Related]
19. Novel 3-arylideneindolin-2-ones as inhibitors of NAD+ -dependent histone deacetylases (sirtuins).
Huber K; Schemies J; Uciechowska U; Wagner JM; Rumpf T; Lewrick F; Süss R; Sippl W; Jung M; Bracher F
J Med Chem; 2010 Feb; 53(3):1383-6. PubMed ID: 20030343
[TBL] [Abstract][Full Text] [Related]
20. Function and regulation of the mitochondrial sirtuin isoform Sirt5 in Mammalia.
Gertz M; Steegborn C
Biochim Biophys Acta; 2010 Aug; 1804(8):1658-65. PubMed ID: 19766741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
